Kinnate Biopharma Competitors

Abcam (NASDAQ:ABCM) and Kinnate Biopharma (NASDAQ:KNTE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Abcam and Kinnate Biopharma, as provided by MarketBeat.

Abcam presently has a consensus price target of $22.00, suggesting a potential upside of 10.61%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Kinnate Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than Abcam.

Profitability

This table compares Abcam and Kinnate Biopharma's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Abcam and Kinnate Biopharma's top-line revenue, earnings per share and valuation.

Summary

Kinnate Biopharma beats Abcam on 3 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Kinnate Biopharma (NASDAQ:KNTE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Seer and Kinnate Biopharma, as provided by MarketBeat.

Seer presently has a consensus price target of $68.00, suggesting a potential upside of 30.79%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Kinnate Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than Seer.

Profitability

This table compares Seer and Kinnate Biopharma's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Seer and Kinnate Biopharma's top-line revenue, earnings per share and valuation.

Summary

Kinnate Biopharma beats Seer on 3 of the 3 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Kinnate Biopharma (NASDAQ:KNTE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Profitability

This table compares Nuvation Bio and Kinnate Biopharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for Nuvation Bio and Kinnate Biopharma, as provided by MarketBeat.

Nuvation Bio presently has a consensus price target of $17.40, suggesting a potential upside of 74.00%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Nuvation Bio's higher probable upside, equities analysts plainly believe Nuvation Bio is more favorable than Kinnate Biopharma.

Earnings and Valuation

This table compares Nuvation Bio and Kinnate Biopharma's top-line revenue, earnings per share and valuation.

Summary

Nuvation Bio beats Kinnate Biopharma on 2 of the 2 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares ImmunityBio and Kinnate Biopharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ImmunityBio and Kinnate Biopharma, as provided by MarketBeat.

ImmunityBio presently has a consensus price target of $25.00, suggesting a potential upside of 48.19%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Kinnate Biopharma's higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than ImmunityBio.

Earnings & Valuation

This table compares ImmunityBio and Kinnate Biopharma's gross revenue, earnings per share and valuation.

Summary

Kinnate Biopharma beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares BioAtla and Kinnate Biopharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BioAtla and Kinnate Biopharma, as provided by MarketBeat.

BioAtla presently has a consensus price target of $58.00, suggesting a potential upside of 22.49%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Kinnate Biopharma's higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than BioAtla.

Earnings & Valuation

This table compares BioAtla and Kinnate Biopharma's gross revenue, earnings per share and valuation.

Summary

Kinnate Biopharma beats BioAtla on 1 of the 1 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares Immunocore and Kinnate Biopharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Immunocore and Kinnate Biopharma, as provided by MarketBeat.

Immunocore presently has a consensus price target of $54.3333, suggesting a potential upside of 53.18%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Kinnate Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than Immunocore.

Earnings & Valuation

This table compares Immunocore and Kinnate Biopharma's gross revenue, earnings per share and valuation.

Summary

Kinnate Biopharma beats Immunocore on 3 of the 3 factors compared between the two stocks.